nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—Flutamide—prostate cancer	0.132	0.347	CbGbCtD
Anagrelide—CYP1A2—Estrone—prostate cancer	0.0954	0.251	CbGbCtD
Anagrelide—CYP1A2—Conjugated Estrogens—prostate cancer	0.0624	0.164	CbGbCtD
Anagrelide—CYP1A2—Estradiol—prostate cancer	0.0548	0.144	CbGbCtD
Anagrelide—CYP1A2—Etoposide—prostate cancer	0.0358	0.0941	CbGbCtD
Anagrelide—PDE3A—penis—prostate cancer	0.0301	0.56	CbGeAlD
Anagrelide—CYP1A2—urine—prostate cancer	0.00887	0.165	CbGeAlD
Anagrelide—PDE3A—prostate gland—prostate cancer	0.00719	0.134	CbGeAlD
Anagrelide—PDE3A—testis—prostate cancer	0.00317	0.0589	CbGeAlD
Anagrelide—PDE3A—lymph node—prostate cancer	0.0023	0.0427	CbGeAlD
Anagrelide—CYP1A2—renal system—prostate cancer	0.00217	0.0403	CbGeAlD
Anagrelide—Hypotension—Docetaxel—prostate cancer	9.47e-05	0.000214	CcSEcCtD
Anagrelide—Haematuria—Doxorubicin—prostate cancer	9.45e-05	0.000214	CcSEcCtD
Anagrelide—Connective tissue disorder—Epirubicin—prostate cancer	9.45e-05	0.000214	CcSEcCtD
Anagrelide—Urethral disorder—Epirubicin—prostate cancer	9.43e-05	0.000214	CcSEcCtD
Anagrelide—Loss of consciousness—Prednisone—prostate cancer	9.41e-05	0.000213	CcSEcCtD
Anagrelide—Hepatobiliary disease—Doxorubicin—prostate cancer	9.38e-05	0.000212	CcSEcCtD
Anagrelide—Epistaxis—Doxorubicin—prostate cancer	9.35e-05	0.000212	CcSEcCtD
Anagrelide—Anorexia—Capecitabine—prostate cancer	9.35e-05	0.000212	CcSEcCtD
Anagrelide—Nausea—Estradiol—prostate cancer	9.34e-05	0.000212	CcSEcCtD
Anagrelide—Vomiting—Mitoxantrone—prostate cancer	9.32e-05	0.000211	CcSEcCtD
Anagrelide—Sinusitis—Doxorubicin—prostate cancer	9.3e-05	0.000211	CcSEcCtD
Anagrelide—Convulsion—Prednisone—prostate cancer	9.28e-05	0.00021	CcSEcCtD
Anagrelide—Visual impairment—Epirubicin—prostate cancer	9.27e-05	0.00021	CcSEcCtD
Anagrelide—Hypertension—Prednisone—prostate cancer	9.24e-05	0.000209	CcSEcCtD
Anagrelide—Rash—Mitoxantrone—prostate cancer	9.24e-05	0.000209	CcSEcCtD
Anagrelide—Dermatitis—Mitoxantrone—prostate cancer	9.23e-05	0.000209	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Docetaxel—prostate cancer	9.23e-05	0.000209	CcSEcCtD
Anagrelide—Headache—Mitoxantrone—prostate cancer	9.18e-05	0.000208	CcSEcCtD
Anagrelide—Hypotension—Capecitabine—prostate cancer	9.17e-05	0.000208	CcSEcCtD
Anagrelide—Insomnia—Docetaxel—prostate cancer	9.16e-05	0.000208	CcSEcCtD
Anagrelide—Myalgia—Prednisone—prostate cancer	9.11e-05	0.000206	CcSEcCtD
Anagrelide—Arthralgia—Prednisone—prostate cancer	9.11e-05	0.000206	CcSEcCtD
Anagrelide—Paraesthesia—Docetaxel—prostate cancer	9.1e-05	0.000206	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	9.05e-05	0.000205	CcSEcCtD
Anagrelide—Dyspnoea—Docetaxel—prostate cancer	9.03e-05	0.000205	CcSEcCtD
Anagrelide—Somnolence—Docetaxel—prostate cancer	9.01e-05	0.000204	CcSEcCtD
Anagrelide—Discomfort—Prednisone—prostate cancer	9e-05	0.000204	CcSEcCtD
Anagrelide—Eye disorder—Epirubicin—prostate cancer	8.99e-05	0.000204	CcSEcCtD
Anagrelide—Tinnitus—Epirubicin—prostate cancer	8.97e-05	0.000203	CcSEcCtD
Anagrelide—Haemoglobin—Doxorubicin—prostate cancer	8.94e-05	0.000203	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Capecitabine—prostate cancer	8.94e-05	0.000202	CcSEcCtD
Anagrelide—Cardiac disorder—Epirubicin—prostate cancer	8.93e-05	0.000202	CcSEcCtD
Anagrelide—Rhinitis—Doxorubicin—prostate cancer	8.92e-05	0.000202	CcSEcCtD
Anagrelide—Dyspepsia—Docetaxel—prostate cancer	8.92e-05	0.000202	CcSEcCtD
Anagrelide—Haemorrhage—Doxorubicin—prostate cancer	8.9e-05	0.000202	CcSEcCtD
Anagrelide—Hepatitis—Doxorubicin—prostate cancer	8.9e-05	0.000202	CcSEcCtD
Anagrelide—Insomnia—Capecitabine—prostate cancer	8.87e-05	0.000201	CcSEcCtD
Anagrelide—Hypoaesthesia—Doxorubicin—prostate cancer	8.85e-05	0.000201	CcSEcCtD
Anagrelide—Pharyngitis—Doxorubicin—prostate cancer	8.83e-05	0.0002	CcSEcCtD
Anagrelide—Paraesthesia—Capecitabine—prostate cancer	8.81e-05	0.000199	CcSEcCtD
Anagrelide—Decreased appetite—Docetaxel—prostate cancer	8.81e-05	0.000199	CcSEcCtD
Anagrelide—Urinary tract disorder—Doxorubicin—prostate cancer	8.79e-05	0.000199	CcSEcCtD
Anagrelide—Oedema peripheral—Doxorubicin—prostate cancer	8.77e-05	0.000199	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Docetaxel—prostate cancer	8.75e-05	0.000198	CcSEcCtD
Anagrelide—Asthenia—Etoposide—prostate cancer	8.75e-05	0.000198	CcSEcCtD
Anagrelide—Connective tissue disorder—Doxorubicin—prostate cancer	8.75e-05	0.000198	CcSEcCtD
Anagrelide—Dyspnoea—Capecitabine—prostate cancer	8.74e-05	0.000198	CcSEcCtD
Anagrelide—Oedema—Prednisone—prostate cancer	8.74e-05	0.000198	CcSEcCtD
Anagrelide—Fatigue—Docetaxel—prostate cancer	8.73e-05	0.000198	CcSEcCtD
Anagrelide—Urethral disorder—Doxorubicin—prostate cancer	8.72e-05	0.000198	CcSEcCtD
Anagrelide—Nausea—Mitoxantrone—prostate cancer	8.7e-05	0.000197	CcSEcCtD
Anagrelide—Infection—Prednisone—prostate cancer	8.68e-05	0.000197	CcSEcCtD
Anagrelide—Mediastinal disorder—Epirubicin—prostate cancer	8.67e-05	0.000196	CcSEcCtD
Anagrelide—Pain—Docetaxel—prostate cancer	8.66e-05	0.000196	CcSEcCtD
Anagrelide—Constipation—Docetaxel—prostate cancer	8.66e-05	0.000196	CcSEcCtD
Anagrelide—Dyspepsia—Capecitabine—prostate cancer	8.63e-05	0.000196	CcSEcCtD
Anagrelide—Chills—Epirubicin—prostate cancer	8.63e-05	0.000195	CcSEcCtD
Anagrelide—Pruritus—Etoposide—prostate cancer	8.62e-05	0.000195	CcSEcCtD
Anagrelide—Shock—Prednisone—prostate cancer	8.6e-05	0.000195	CcSEcCtD
Anagrelide—Arrhythmia—Epirubicin—prostate cancer	8.59e-05	0.000195	CcSEcCtD
Anagrelide—Visual impairment—Doxorubicin—prostate cancer	8.58e-05	0.000194	CcSEcCtD
Anagrelide—Nervous system disorder—Prednisone—prostate cancer	8.57e-05	0.000194	CcSEcCtD
Anagrelide—Tachycardia—Prednisone—prostate cancer	8.53e-05	0.000193	CcSEcCtD
Anagrelide—Decreased appetite—Capecitabine—prostate cancer	8.53e-05	0.000193	CcSEcCtD
Anagrelide—Alopecia—Epirubicin—prostate cancer	8.5e-05	0.000192	CcSEcCtD
Anagrelide—Skin disorder—Prednisone—prostate cancer	8.49e-05	0.000192	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Capecitabine—prostate cancer	8.47e-05	0.000192	CcSEcCtD
Anagrelide—Fatigue—Capecitabine—prostate cancer	8.46e-05	0.000192	CcSEcCtD
Anagrelide—Hyperhidrosis—Prednisone—prostate cancer	8.45e-05	0.000191	CcSEcCtD
Anagrelide—Pain—Capecitabine—prostate cancer	8.39e-05	0.00019	CcSEcCtD
Anagrelide—Constipation—Capecitabine—prostate cancer	8.39e-05	0.00019	CcSEcCtD
Anagrelide—Malnutrition—Epirubicin—prostate cancer	8.37e-05	0.00019	CcSEcCtD
Anagrelide—Feeling abnormal—Docetaxel—prostate cancer	8.35e-05	0.000189	CcSEcCtD
Anagrelide—Diarrhoea—Etoposide—prostate cancer	8.34e-05	0.000189	CcSEcCtD
Anagrelide—Anorexia—Prednisone—prostate cancer	8.33e-05	0.000189	CcSEcCtD
Anagrelide—Eye disorder—Doxorubicin—prostate cancer	8.32e-05	0.000188	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—prostate cancer	8.3e-05	0.000188	CcSEcCtD
Anagrelide—Gastrointestinal pain—Docetaxel—prostate cancer	8.28e-05	0.000188	CcSEcCtD
Anagrelide—Cardiac disorder—Doxorubicin—prostate cancer	8.26e-05	0.000187	CcSEcCtD
Anagrelide—Flatulence—Epirubicin—prostate cancer	8.25e-05	0.000187	CcSEcCtD
Anagrelide—Tension—Epirubicin—prostate cancer	8.22e-05	0.000186	CcSEcCtD
Anagrelide—Nervousness—Epirubicin—prostate cancer	8.13e-05	0.000184	CcSEcCtD
Anagrelide—Back pain—Epirubicin—prostate cancer	8.1e-05	0.000183	CcSEcCtD
Anagrelide—Feeling abnormal—Capecitabine—prostate cancer	8.08e-05	0.000183	CcSEcCtD
Anagrelide—Dizziness—Etoposide—prostate cancer	8.06e-05	0.000183	CcSEcCtD
Anagrelide—Muscle spasms—Epirubicin—prostate cancer	8.05e-05	0.000182	CcSEcCtD
Anagrelide—Gastrointestinal pain—Capecitabine—prostate cancer	8.02e-05	0.000182	CcSEcCtD
Anagrelide—Mediastinal disorder—Doxorubicin—prostate cancer	8.02e-05	0.000182	CcSEcCtD
Anagrelide—Abdominal pain—Docetaxel—prostate cancer	8.01e-05	0.000181	CcSEcCtD
Anagrelide—Body temperature increased—Docetaxel—prostate cancer	8.01e-05	0.000181	CcSEcCtD
Anagrelide—Chills—Doxorubicin—prostate cancer	7.98e-05	0.000181	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Prednisone—prostate cancer	7.96e-05	0.00018	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—prostate cancer	7.95e-05	0.00018	CcSEcCtD
Anagrelide—Insomnia—Prednisone—prostate cancer	7.9e-05	0.000179	CcSEcCtD
Anagrelide—Vision blurred—Epirubicin—prostate cancer	7.89e-05	0.000179	CcSEcCtD
Anagrelide—Alopecia—Doxorubicin—prostate cancer	7.86e-05	0.000178	CcSEcCtD
Anagrelide—Paraesthesia—Prednisone—prostate cancer	7.85e-05	0.000178	CcSEcCtD
Anagrelide—Urticaria—Capecitabine—prostate cancer	7.79e-05	0.000176	CcSEcCtD
Anagrelide—Ill-defined disorder—Epirubicin—prostate cancer	7.77e-05	0.000176	CcSEcCtD
Anagrelide—Abdominal pain—Capecitabine—prostate cancer	7.75e-05	0.000176	CcSEcCtD
Anagrelide—Body temperature increased—Capecitabine—prostate cancer	7.75e-05	0.000176	CcSEcCtD
Anagrelide—Vomiting—Etoposide—prostate cancer	7.75e-05	0.000176	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—prostate cancer	7.75e-05	0.000175	CcSEcCtD
Anagrelide—Anaemia—Epirubicin—prostate cancer	7.74e-05	0.000175	CcSEcCtD
Anagrelide—Dyspepsia—Prednisone—prostate cancer	7.69e-05	0.000174	CcSEcCtD
Anagrelide—Rash—Etoposide—prostate cancer	7.69e-05	0.000174	CcSEcCtD
Anagrelide—Dermatitis—Etoposide—prostate cancer	7.68e-05	0.000174	CcSEcCtD
Anagrelide—Headache—Etoposide—prostate cancer	7.64e-05	0.000173	CcSEcCtD
Anagrelide—Flatulence—Doxorubicin—prostate cancer	7.63e-05	0.000173	CcSEcCtD
Anagrelide—Tension—Doxorubicin—prostate cancer	7.6e-05	0.000172	CcSEcCtD
Anagrelide—Decreased appetite—Prednisone—prostate cancer	7.59e-05	0.000172	CcSEcCtD
Anagrelide—Malaise—Epirubicin—prostate cancer	7.55e-05	0.000171	CcSEcCtD
Anagrelide—Fatigue—Prednisone—prostate cancer	7.53e-05	0.000171	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—prostate cancer	7.52e-05	0.00017	CcSEcCtD
Anagrelide—Syncope—Epirubicin—prostate cancer	7.51e-05	0.00017	CcSEcCtD
Anagrelide—Back pain—Doxorubicin—prostate cancer	7.49e-05	0.00017	CcSEcCtD
Anagrelide—Constipation—Prednisone—prostate cancer	7.47e-05	0.000169	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—prostate cancer	7.45e-05	0.000169	CcSEcCtD
Anagrelide—Palpitations—Epirubicin—prostate cancer	7.4e-05	0.000168	CcSEcCtD
Anagrelide—Loss of consciousness—Epirubicin—prostate cancer	7.36e-05	0.000167	CcSEcCtD
Anagrelide—Cough—Epirubicin—prostate cancer	7.31e-05	0.000165	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—prostate cancer	7.3e-05	0.000165	CcSEcCtD
Anagrelide—Asthenia—Docetaxel—prostate cancer	7.27e-05	0.000165	CcSEcCtD
Anagrelide—Convulsion—Epirubicin—prostate cancer	7.25e-05	0.000164	CcSEcCtD
Anagrelide—Nausea—Etoposide—prostate cancer	7.24e-05	0.000164	CcSEcCtD
Anagrelide—Hypertension—Epirubicin—prostate cancer	7.23e-05	0.000164	CcSEcCtD
Anagrelide—Feeling abnormal—Prednisone—prostate cancer	7.2e-05	0.000163	CcSEcCtD
Anagrelide—Ill-defined disorder—Doxorubicin—prostate cancer	7.19e-05	0.000163	CcSEcCtD
Anagrelide—Pruritus—Docetaxel—prostate cancer	7.17e-05	0.000162	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—prostate cancer	7.16e-05	0.000162	CcSEcCtD
Anagrelide—Gastrointestinal pain—Prednisone—prostate cancer	7.14e-05	0.000162	CcSEcCtD
Anagrelide—Myalgia—Epirubicin—prostate cancer	7.13e-05	0.000161	CcSEcCtD
Anagrelide—Arthralgia—Epirubicin—prostate cancer	7.13e-05	0.000161	CcSEcCtD
Anagrelide—Chest pain—Epirubicin—prostate cancer	7.13e-05	0.000161	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP7B1—prostate cancer	7.09e-05	0.000569	CbGpPWpGaD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	7.08e-05	0.00016	CcSEcCtD
Anagrelide—Discomfort—Epirubicin—prostate cancer	7.04e-05	0.000159	CcSEcCtD
Anagrelide—Asthenia—Capecitabine—prostate cancer	7.04e-05	0.000159	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—COMT—prostate cancer	7.02e-05	0.000564	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTP1—prostate cancer	6.99e-05	0.000562	CbGpPWpGaD
Anagrelide—Malaise—Doxorubicin—prostate cancer	6.99e-05	0.000158	CcSEcCtD
Anagrelide—Dry mouth—Epirubicin—prostate cancer	6.97e-05	0.000158	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—prostate cancer	6.96e-05	0.00056	CbGpPWpGaD
Anagrelide—Syncope—Doxorubicin—prostate cancer	6.95e-05	0.000157	CcSEcCtD
Anagrelide—Urticaria—Prednisone—prostate cancer	6.94e-05	0.000157	CcSEcCtD
Anagrelide—Pruritus—Capecitabine—prostate cancer	6.94e-05	0.000157	CcSEcCtD
Anagrelide—Diarrhoea—Docetaxel—prostate cancer	6.93e-05	0.000157	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—COMT—prostate cancer	6.92e-05	0.000556	CbGpPWpGaD
Anagrelide—Abdominal pain—Prednisone—prostate cancer	6.91e-05	0.000156	CcSEcCtD
Anagrelide—Body temperature increased—Prednisone—prostate cancer	6.91e-05	0.000156	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A1—prostate cancer	6.91e-05	0.000555	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTP1—prostate cancer	6.89e-05	0.000554	CbGpPWpGaD
Anagrelide—Confusional state—Epirubicin—prostate cancer	6.89e-05	0.000156	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—IL2—prostate cancer	6.86e-05	0.000551	CbGpPWpGaD
Anagrelide—Palpitations—Doxorubicin—prostate cancer	6.85e-05	0.000155	CcSEcCtD
Anagrelide—Oedema—Epirubicin—prostate cancer	6.83e-05	0.000155	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PTHLH—prostate cancer	6.83e-05	0.000549	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFBR1—prostate cancer	6.83e-05	0.000549	CbGpPWpGaD
Anagrelide—Loss of consciousness—Doxorubicin—prostate cancer	6.81e-05	0.000154	CcSEcCtD
Anagrelide—Infection—Epirubicin—prostate cancer	6.79e-05	0.000154	CcSEcCtD
Anagrelide—Cough—Doxorubicin—prostate cancer	6.76e-05	0.000153	CcSEcCtD
Anagrelide—Shock—Epirubicin—prostate cancer	6.72e-05	0.000152	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—AKR1C3—prostate cancer	6.72e-05	0.00054	CbGpPWpGaD
Anagrelide—Convulsion—Doxorubicin—prostate cancer	6.71e-05	0.000152	CcSEcCtD
Anagrelide—Diarrhoea—Capecitabine—prostate cancer	6.71e-05	0.000152	CcSEcCtD
Anagrelide—Nervous system disorder—Epirubicin—prostate cancer	6.7e-05	0.000152	CcSEcCtD
Anagrelide—Dizziness—Docetaxel—prostate cancer	6.7e-05	0.000152	CcSEcCtD
Anagrelide—Thrombocytopenia—Epirubicin—prostate cancer	6.69e-05	0.000152	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—prostate cancer	6.69e-05	0.000151	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PRKACB—prostate cancer	6.69e-05	0.000537	CbGpPWpGaD
Anagrelide—Tachycardia—Epirubicin—prostate cancer	6.67e-05	0.000151	CcSEcCtD
Anagrelide—Skin disorder—Epirubicin—prostate cancer	6.64e-05	0.00015	CcSEcCtD
Anagrelide—Hyperhidrosis—Epirubicin—prostate cancer	6.61e-05	0.00015	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—prostate cancer	6.6e-05	0.000149	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—prostate cancer	6.6e-05	0.000149	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—prostate cancer	6.6e-05	0.000149	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ACSL4—prostate cancer	6.59e-05	0.000529	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B3—prostate cancer	6.59e-05	0.000529	CbGpPWpGaD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.55e-05	0.000148	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—THBS1—prostate cancer	6.52e-05	0.000524	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PPP3CA—prostate cancer	6.52e-05	0.000524	CbGpPWpGaD
Anagrelide—Discomfort—Doxorubicin—prostate cancer	6.52e-05	0.000148	CcSEcCtD
Anagrelide—Anorexia—Epirubicin—prostate cancer	6.51e-05	0.000148	CcSEcCtD
Anagrelide—Dizziness—Capecitabine—prostate cancer	6.49e-05	0.000147	CcSEcCtD
Anagrelide—Dry mouth—Doxorubicin—prostate cancer	6.45e-05	0.000146	CcSEcCtD
Anagrelide—Vomiting—Docetaxel—prostate cancer	6.44e-05	0.000146	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ANXA1—prostate cancer	6.42e-05	0.000516	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTM1—prostate cancer	6.42e-05	0.000516	CbGpPWpGaD
Anagrelide—Rash—Docetaxel—prostate cancer	6.39e-05	0.000145	CcSEcCtD
Anagrelide—Hypotension—Epirubicin—prostate cancer	6.39e-05	0.000145	CcSEcCtD
Anagrelide—Dermatitis—Docetaxel—prostate cancer	6.38e-05	0.000145	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—prostate cancer	6.38e-05	0.000144	CcSEcCtD
Anagrelide—Headache—Docetaxel—prostate cancer	6.35e-05	0.000144	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTM1—prostate cancer	6.33e-05	0.000509	CbGpPWpGaD
Anagrelide—Oedema—Doxorubicin—prostate cancer	6.32e-05	0.000143	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PRKCZ—prostate cancer	6.3e-05	0.000507	CbGpPWpGaD
Anagrelide—Infection—Doxorubicin—prostate cancer	6.28e-05	0.000142	CcSEcCtD
Anagrelide—Asthenia—Prednisone—prostate cancer	6.27e-05	0.000142	CcSEcCtD
Anagrelide—Vomiting—Capecitabine—prostate cancer	6.24e-05	0.000141	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Epirubicin—prostate cancer	6.23e-05	0.000141	CcSEcCtD
Anagrelide—Shock—Doxorubicin—prostate cancer	6.22e-05	0.000141	CcSEcCtD
Anagrelide—Nervous system disorder—Doxorubicin—prostate cancer	6.2e-05	0.00014	CcSEcCtD
Anagrelide—Thrombocytopenia—Doxorubicin—prostate cancer	6.19e-05	0.00014	CcSEcCtD
Anagrelide—Rash—Capecitabine—prostate cancer	6.18e-05	0.00014	CcSEcCtD
Anagrelide—Pruritus—Prednisone—prostate cancer	6.18e-05	0.00014	CcSEcCtD
Anagrelide—Insomnia—Epirubicin—prostate cancer	6.18e-05	0.00014	CcSEcCtD
Anagrelide—Dermatitis—Capecitabine—prostate cancer	6.18e-05	0.00014	CcSEcCtD
Anagrelide—Tachycardia—Doxorubicin—prostate cancer	6.17e-05	0.00014	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CG—prostate cancer	6.16e-05	0.000495	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—EP300—prostate cancer	6.16e-05	0.000495	CbGpPWpGaD
Anagrelide—Headache—Capecitabine—prostate cancer	6.14e-05	0.000139	CcSEcCtD
Anagrelide—Skin disorder—Doxorubicin—prostate cancer	6.14e-05	0.000139	CcSEcCtD
Anagrelide—Paraesthesia—Epirubicin—prostate cancer	6.14e-05	0.000139	CcSEcCtD
Anagrelide—Hyperhidrosis—Doxorubicin—prostate cancer	6.11e-05	0.000138	CcSEcCtD
Anagrelide—Dyspnoea—Epirubicin—prostate cancer	6.09e-05	0.000138	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—FGFR4—prostate cancer	6.09e-05	0.000489	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PARP1—prostate cancer	6.09e-05	0.000489	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP1A1—prostate cancer	6.09e-05	0.000489	CbGpPWpGaD
Anagrelide—Somnolence—Epirubicin—prostate cancer	6.07e-05	0.000138	CcSEcCtD
Anagrelide—Anorexia—Doxorubicin—prostate cancer	6.03e-05	0.000136	CcSEcCtD
Anagrelide—Nausea—Docetaxel—prostate cancer	6.02e-05	0.000136	CcSEcCtD
Anagrelide—Dyspepsia—Epirubicin—prostate cancer	6.01e-05	0.000136	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CALCA—prostate cancer	6.01e-05	0.000483	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HAO1—prostate cancer	6.01e-05	0.000483	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP1A1—prostate cancer	6e-05	0.000482	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SRC—prostate cancer	5.99e-05	0.000481	CbGpPWpGaD
Anagrelide—Diarrhoea—Prednisone—prostate cancer	5.98e-05	0.000135	CcSEcCtD
Anagrelide—Decreased appetite—Epirubicin—prostate cancer	5.94e-05	0.000135	CcSEcCtD
Anagrelide—Hypotension—Doxorubicin—prostate cancer	5.91e-05	0.000134	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Epirubicin—prostate cancer	5.9e-05	0.000134	CcSEcCtD
Anagrelide—Fatigue—Epirubicin—prostate cancer	5.89e-05	0.000133	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CXCL12—prostate cancer	5.87e-05	0.000472	CbGpPWpGaD
Anagrelide—Constipation—Epirubicin—prostate cancer	5.84e-05	0.000132	CcSEcCtD
Anagrelide—Pain—Epirubicin—prostate cancer	5.84e-05	0.000132	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—VEGFA—prostate cancer	5.83e-05	0.000469	CbGpPWpGaD
Anagrelide—Nausea—Capecitabine—prostate cancer	5.83e-05	0.000132	CcSEcCtD
Anagrelide—Dizziness—Prednisone—prostate cancer	5.78e-05	0.000131	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.76e-05	0.00013	CcSEcCtD
Anagrelide—Insomnia—Doxorubicin—prostate cancer	5.72e-05	0.00013	CcSEcCtD
Anagrelide—Paraesthesia—Doxorubicin—prostate cancer	5.68e-05	0.000129	CcSEcCtD
Anagrelide—Dyspnoea—Doxorubicin—prostate cancer	5.64e-05	0.000128	CcSEcCtD
Anagrelide—Feeling abnormal—Epirubicin—prostate cancer	5.63e-05	0.000128	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—prostate cancer	5.62e-05	0.000127	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B1—prostate cancer	5.6e-05	0.00045	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CG—prostate cancer	5.6e-05	0.00045	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Epirubicin—prostate cancer	5.59e-05	0.000127	CcSEcCtD
Anagrelide—Dyspepsia—Doxorubicin—prostate cancer	5.57e-05	0.000126	CcSEcCtD
Anagrelide—Vomiting—Prednisone—prostate cancer	5.55e-05	0.000126	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CASP9—prostate cancer	5.53e-05	0.000445	CbGpPWpGaD
Anagrelide—Rash—Prednisone—prostate cancer	5.51e-05	0.000125	CcSEcCtD
Anagrelide—Dermatitis—Prednisone—prostate cancer	5.5e-05	0.000125	CcSEcCtD
Anagrelide—Decreased appetite—Doxorubicin—prostate cancer	5.5e-05	0.000124	CcSEcCtD
Anagrelide—Headache—Prednisone—prostate cancer	5.47e-05	0.000124	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.46e-05	0.000124	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—prostate cancer	5.45e-05	0.000123	CcSEcCtD
Anagrelide—Urticaria—Epirubicin—prostate cancer	5.43e-05	0.000123	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CD—prostate cancer	5.42e-05	0.000435	CbGpPWpGaD
Anagrelide—Pain—Doxorubicin—prostate cancer	5.41e-05	0.000122	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—prostate cancer	5.41e-05	0.000122	CcSEcCtD
Anagrelide—Abdominal pain—Epirubicin—prostate cancer	5.4e-05	0.000122	CcSEcCtD
Anagrelide—Body temperature increased—Epirubicin—prostate cancer	5.4e-05	0.000122	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—TBXAS1—prostate cancer	5.37e-05	0.000432	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCQ—prostate cancer	5.36e-05	0.000431	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NGFR—prostate cancer	5.36e-05	0.000431	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TGFB1—prostate cancer	5.35e-05	0.00043	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAP3K7—prostate cancer	5.3e-05	0.000426	CbGpPWpGaD
Anagrelide—Feeling abnormal—Doxorubicin—prostate cancer	5.21e-05	0.000118	CcSEcCtD
Anagrelide—Nausea—Prednisone—prostate cancer	5.19e-05	0.000118	CcSEcCtD
Anagrelide—Gastrointestinal pain—Doxorubicin—prostate cancer	5.17e-05	0.000117	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ABCG5—prostate cancer	5.17e-05	0.000415	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF10—prostate cancer	5.09e-05	0.000409	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRB2—prostate cancer	5.04e-05	0.000405	CbGpPWpGaD
Anagrelide—Urticaria—Doxorubicin—prostate cancer	5.02e-05	0.000114	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—prostate cancer	5e-05	0.000113	CcSEcCtD
Anagrelide—Abdominal pain—Doxorubicin—prostate cancer	5e-05	0.000113	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B2—prostate cancer	4.99e-05	0.000401	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—JAK2—prostate cancer	4.97e-05	0.000399	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—KRAS—prostate cancer	4.96e-05	0.000398	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAP2K1—prostate cancer	4.95e-05	0.000398	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CD—prostate cancer	4.92e-05	0.000395	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VAV3—prostate cancer	4.91e-05	0.000395	CbGpPWpGaD
Anagrelide—Asthenia—Epirubicin—prostate cancer	4.9e-05	0.000111	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—PSAT1—prostate cancer	4.9e-05	0.000394	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GRHL1—prostate cancer	4.9e-05	0.000394	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CBR1—prostate cancer	4.9e-05	0.000394	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TST—prostate cancer	4.9e-05	0.000394	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADI1—prostate cancer	4.9e-05	0.000394	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CSAD—prostate cancer	4.9e-05	0.000394	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFBR2—prostate cancer	4.84e-05	0.000389	CbGpPWpGaD
Anagrelide—Pruritus—Epirubicin—prostate cancer	4.83e-05	0.000109	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LRP2—prostate cancer	4.79e-05	0.000385	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ITPR1—prostate cancer	4.77e-05	0.000383	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CB—prostate cancer	4.72e-05	0.000379	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—prostate cancer	4.69e-05	0.000377	CbGpPWpGaD
Anagrelide—Diarrhoea—Epirubicin—prostate cancer	4.68e-05	0.000106	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—IGF1R—prostate cancer	4.56e-05	0.000366	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CA—prostate cancer	4.55e-05	0.000366	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UGT2B17—prostate cancer	4.55e-05	0.000366	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UGT2B15—prostate cancer	4.55e-05	0.000366	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CKMT2—prostate cancer	4.55e-05	0.000366	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GRHPR—prostate cancer	4.55e-05	0.000366	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL8—prostate cancer	4.54e-05	0.000365	CbGpPWpGaD
Anagrelide—Asthenia—Doxorubicin—prostate cancer	4.54e-05	0.000103	CcSEcCtD
Anagrelide—Dizziness—Epirubicin—prostate cancer	4.52e-05	0.000102	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—JAK2—prostate cancer	4.51e-05	0.000363	CbGpPWpGaD
Anagrelide—Pruritus—Doxorubicin—prostate cancer	4.47e-05	0.000101	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	4.45e-05	0.000358	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TP53—prostate cancer	4.41e-05	0.000354	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—MED12—prostate cancer	4.38e-05	0.000352	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LPL—prostate cancer	4.37e-05	0.000351	CbGpPWpGaD
Anagrelide—Vomiting—Epirubicin—prostate cancer	4.34e-05	9.84e-05	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—IL2—prostate cancer	4.34e-05	0.000348	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDGFRB—prostate cancer	4.33e-05	0.000348	CbGpPWpGaD
Anagrelide—Diarrhoea—Doxorubicin—prostate cancer	4.33e-05	9.8e-05	CcSEcCtD
Anagrelide—Rash—Epirubicin—prostate cancer	4.31e-05	9.76e-05	CcSEcCtD
Anagrelide—Dermatitis—Epirubicin—prostate cancer	4.3e-05	9.75e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CB—prostate cancer	4.29e-05	0.000345	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AOX1—prostate cancer	4.28e-05	0.000344	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—RFK—prostate cancer	4.28e-05	0.000344	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NAGLU—prostate cancer	4.28e-05	0.000344	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PGAM2—prostate cancer	4.28e-05	0.000344	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SULT2B1—prostate cancer	4.28e-05	0.000344	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM3—prostate cancer	4.28e-05	0.000344	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MBTPS1—prostate cancer	4.28e-05	0.000344	CbGpPWpGaD
Anagrelide—Headache—Epirubicin—prostate cancer	4.28e-05	9.69e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ITGB3—prostate cancer	4.22e-05	0.000339	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	4.18e-05	0.000336	CbGpPWpGaD
Anagrelide—Dizziness—Doxorubicin—prostate cancer	4.18e-05	9.47e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CXCL8—prostate cancer	4.12e-05	0.000331	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ERBB3—prostate cancer	4.09e-05	0.000329	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGFR2—prostate cancer	4.09e-05	0.000328	CbGpPWpGaD
Anagrelide—Nausea—Epirubicin—prostate cancer	4.06e-05	9.19e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—CYP3A43—prostate cancer	4.06e-05	0.000326	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AMACR—prostate cancer	4.06e-05	0.000326	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NAT1—prostate cancer	4.06e-05	0.000326	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—DEGS1—prostate cancer	4.06e-05	0.000326	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SRD5A2—prostate cancer	4.06e-05	0.000326	CbGpPWpGaD
Anagrelide—Vomiting—Doxorubicin—prostate cancer	4.02e-05	9.1e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	3.99e-05	0.000321	CbGpPWpGaD
Anagrelide—Rash—Doxorubicin—prostate cancer	3.99e-05	9.03e-05	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—prostate cancer	3.98e-05	9.02e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	3.97e-05	0.000319	CbGpPWpGaD
Anagrelide—Headache—Doxorubicin—prostate cancer	3.96e-05	8.97e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—IL2—prostate cancer	3.94e-05	0.000316	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TERT—prostate cancer	3.92e-05	0.000315	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD17B1—prostate cancer	3.87e-05	0.000311	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	3.87e-05	0.000311	CbGpPWpGaD
Anagrelide—Nausea—Doxorubicin—prostate cancer	3.76e-05	8.5e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—HIF1A—prostate cancer	3.75e-05	0.000302	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	3.72e-05	0.000299	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT1—prostate cancer	3.72e-05	0.000299	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	3.7e-05	0.000298	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	3.66e-05	0.000294	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LEP—prostate cancer	3.66e-05	0.000294	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CAV1—prostate cancer	3.63e-05	0.000292	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KDR—prostate cancer	3.59e-05	0.000288	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ESR1—prostate cancer	3.5e-05	0.000281	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	3.49e-05	0.000281	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—B4GALT4—prostate cancer	3.45e-05	0.000277	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HPGD—prostate cancer	3.45e-05	0.000277	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BAD—prostate cancer	3.41e-05	0.000274	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APC—prostate cancer	3.31e-05	0.000266	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CG—prostate cancer	3.31e-05	0.000266	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGF—prostate cancer	3.27e-05	0.000263	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IRS1—prostate cancer	3.27e-05	0.000263	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TNFRSF21—prostate cancer	3.24e-05	0.000261	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GSK3B—prostate cancer	3.17e-05	0.000255	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP7B1—prostate cancer	3.16e-05	0.000254	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTAP—prostate cancer	3.16e-05	0.000254	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—INS—prostate cancer	3.13e-05	0.000251	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	3.08e-05	0.000248	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SULT1E1—prostate cancer	3.08e-05	0.000247	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SRD5A1—prostate cancer	3.08e-05	0.000247	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CREBBP—prostate cancer	3.06e-05	0.000246	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1—prostate cancer	3.03e-05	0.000243	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EGFR—prostate cancer	3.01e-05	0.000242	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	2.99e-05	0.00024	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	2.94e-05	0.000236	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ACSL4—prostate cancer	2.93e-05	0.000236	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD17B3—prostate cancer	2.93e-05	0.000236	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAP2K1—prostate cancer	2.93e-05	0.000235	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CD—prostate cancer	2.91e-05	0.000234	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	2.9e-05	0.000233	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CA—prostate cancer	2.88e-05	0.000231	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SERPINE1—prostate cancer	2.87e-05	0.000231	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—KRAS—prostate cancer	2.85e-05	0.000229	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PHGDH—prostate cancer	2.81e-05	0.000226	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UMPS—prostate cancer	2.81e-05	0.000226	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ARG2—prostate cancer	2.81e-05	0.000226	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	2.8e-05	0.000225	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF2—prostate cancer	2.78e-05	0.000224	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LDHB—prostate cancer	2.76e-05	0.000222	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOS3—prostate cancer	2.74e-05	0.00022	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP3A5—prostate cancer	2.71e-05	0.000218	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JAK2—prostate cancer	2.67e-05	0.000214	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PDHA1—prostate cancer	2.62e-05	0.00021	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA3—prostate cancer	2.62e-05	0.00021	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TCN2—prostate cancer	2.62e-05	0.00021	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UCP3—prostate cancer	2.62e-05	0.00021	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CA—prostate cancer	2.61e-05	0.00021	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MDM2—prostate cancer	2.6e-05	0.000209	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ERBB2—prostate cancer	2.57e-05	0.000206	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CB—prostate cancer	2.53e-05	0.000204	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD3B1—prostate cancer	2.49e-05	0.0002	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC22A3—prostate cancer	2.49e-05	0.0002	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL8—prostate cancer	2.43e-05	0.000196	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—prostate cancer	2.42e-05	0.000194	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA4—prostate cancer	2.39e-05	0.000192	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TBXAS1—prostate cancer	2.39e-05	0.000192	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1B—prostate cancer	2.38e-05	0.000191	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—prostate cancer	2.35e-05	0.000189	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	2.34e-05	0.000188	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA2—prostate cancer	2.33e-05	0.000187	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP3—prostate cancer	2.33e-05	0.000187	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL2—prostate cancer	2.33e-05	0.000187	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—prostate cancer	2.31e-05	0.000186	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SULT1A1—prostate cancer	2.3e-05	0.000185	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCG5—prostate cancer	2.3e-05	0.000185	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCND1—prostate cancer	2.27e-05	0.000182	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA1—prostate cancer	2.25e-05	0.000181	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CTNNB1—prostate cancer	2.25e-05	0.00018	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD3B2—prostate cancer	2.22e-05	0.000179	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTO1—prostate cancer	2.22e-05	0.000179	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NAT2—prostate cancer	2.22e-05	0.000179	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—prostate cancer	2.2e-05	0.000177	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1A—prostate cancer	2.19e-05	0.000176	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTEN—prostate cancer	2.19e-05	0.000176	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	2.14e-05	0.000172	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—prostate cancer	2.14e-05	0.000172	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLCB2—prostate cancer	2.13e-05	0.000171	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2C18—prostate cancer	2.13e-05	0.000171	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LRP2—prostate cancer	2.13e-05	0.000171	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—P4HB—prostate cancer	2.09e-05	0.000168	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EP300—prostate cancer	2.09e-05	0.000168	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC22A1—prostate cancer	2.03e-05	0.000163	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SRC—prostate cancer	2.03e-05	0.000163	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	2.01e-05	0.000162	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SULT2A1—prostate cancer	1.98e-05	0.000159	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—prostate cancer	1.98e-05	0.000159	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STAT3—prostate cancer	1.96e-05	0.000157	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MED12—prostate cancer	1.95e-05	0.000157	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GNG5—prostate cancer	1.93e-05	0.000155	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NCOA3—prostate cancer	1.86e-05	0.00015	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.83e-05	0.000147	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MYC—prostate cancer	1.82e-05	0.000146	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFB1—prostate cancer	1.81e-05	0.000146	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGFR—prostate cancer	1.78e-05	0.000143	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HPGDS—prostate cancer	1.78e-05	0.000143	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2C19—prostate cancer	1.77e-05	0.000142	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ACHE—prostate cancer	1.72e-05	0.000139	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTT1—prostate cancer	1.72e-05	0.000139	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2A6—prostate cancer	1.7e-05	0.000137	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.7e-05	0.000136	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KRAS—prostate cancer	1.68e-05	0.000135	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKR1C3—prostate cancer	1.66e-05	0.000133	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PRKACB—prostate cancer	1.65e-05	0.000133	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP17A1—prostate cancer	1.63e-05	0.000131	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.61e-05	0.000129	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NCOA2—prostate cancer	1.56e-05	0.000125	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CA—prostate cancer	1.54e-05	0.000124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TP53—prostate cancer	1.49e-05	0.00012	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC5A5—prostate cancer	1.48e-05	0.000119	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2E1—prostate cancer	1.45e-05	0.000116	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NQO1—prostate cancer	1.43e-05	0.000115	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TH—prostate cancer	1.41e-05	0.000113	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.4e-05	0.000113	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP3A4—prostate cancer	1.4e-05	0.000112	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.39e-05	0.000112	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP1B1—prostate cancer	1.37e-05	0.00011	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—prostate cancer	1.37e-05	0.00011	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GGT1—prostate cancer	1.33e-05	0.000107	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NCOA1—prostate cancer	1.31e-05	0.000105	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP19A1—prostate cancer	1.29e-05	0.000104	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—prostate cancer	1.26e-05	0.000101	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—RXRA—prostate cancer	1.25e-05	0.0001	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.21e-05	9.74e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—COMT—prostate cancer	1.2e-05	9.65e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTP1—prostate cancer	1.2e-05	9.6e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ITPR1—prostate cancer	1.18e-05	9.45e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.16e-05	9.29e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TYMS—prostate cancer	1.11e-05	8.93e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—prostate cancer	1.1e-05	8.82e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPL—prostate cancer	1.08e-05	8.66e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.04e-05	8.37e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ERCC2—prostate cancer	1.03e-05	8.3e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTHFR—prostate cancer	9.71e-06	7.8e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARA—prostate cancer	9.52e-06	7.65e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CAV1—prostate cancer	8.95e-06	7.19e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.55e-06	6.87e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CG—prostate cancer	8.15e-06	6.55e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—INS—prostate cancer	7.72e-06	6.2e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CREBBP—prostate cancer	7.56e-06	6.08e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CD—prostate cancer	7.17e-06	5.76e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NOS3—prostate cancer	6.77e-06	5.44e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CB—prostate cancer	6.25e-06	5.02e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—prostate cancer	6.19e-06	4.97e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTEN—prostate cancer	5.4e-06	4.34e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—EP300—prostate cancer	5.15e-06	4.14e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CA—prostate cancer	3.81e-06	3.06e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—prostate cancer	3.11e-06	2.5e-05	CbGpPWpGaD
